ClinicalTrials.Veeva

Menu

Tracing Changed Production of Red Blood Cells

University of Copenhagen logo

University of Copenhagen

Status

Completed

Conditions

Erythrocytosis
Erythropoiesis Abnormal

Treatments

Drug: Recombinant human erythropoietin

Study type

Interventional

Funder types

Other

Identifiers

NCT05833477
H-20064997

Details and patient eligibility

About

In competitive sport, it is illegal to manipulate erythropoiesis. Manipulated erythropoiesis can indirectly be identified by atypical fluctuations in key haematological variables. However, this method also has limitations and as it is known that some athletes still manipulate erythropoiesis it is necessary to develop new and more sensitive detection methods.

The primary purpose of the study is to examine the importance of altered erythropoiesis for surface and intracellular erythrocyte proteins, the number of immature reticulocytes, and for the haematological characteristics of the erythrocyte, such as volume, haemoglobin concentration and concentration of glycosylated haemoglobin, to assess whether these can be used to identify changed erythropoiesis. Furthermore, the aim is to examine whether these parameters are affected by freezer storage of erythrocytes.

Enrollment

12 patients

Sex

Male

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy men
  • 18-40 years
  • physical fitness rating more than 50ml/kg/min
  • non-smokers
  • blood pressure <130/90 mmHg
  • hemoglobin concentration 7-10.5 mM.

Exclusion criteria

  • Blood donor who has donated blood within the last three months
  • Participation in other concurrent clinical trials
  • To participate in competitive sport during or three months after the study.

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

12 participants in 1 patient group

Treatment group
Experimental group
Description:
Recombinant human erythropoietin treatment three times per week for three weeks
Treatment:
Drug: Recombinant human erythropoietin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems